

## Curriculum Vitae

*\*CV must be written in English*

### Personal Information



<b>Title</b> (i.e. Prof., Dr., etc.)	Dr.
<b>Name</b> (First / Middle / Last)	Joyce Wing Yan Mak
<b>Degree</b> (i.e. MD, MSc, PhD, etc.)	PhD
<b>Country</b>	Hong Kong SAR
<b>Affiliation</b>	The Chinese University of Hong Kong

### Educational Background

MBBS, MRCP (UK), FHKCP, FHKAM (Medicine), PhD (CUHK), FRCP (London)

### Professional Experience

Head (Clinical), Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, Prince of Wales Hospital

Consultant, Department of Medicine and Therapeutics, Prince of Wales Hospital

Honorary Clinical Associate Professor, Department of Medicine and Therapeutics, The Chinese University of Hong Kong

### Professional Organizations

2026 – Now Member, World Gastroenterology Organisation (WGO) IBD Committee

2025 – Now Immediate Past President, Hong Kong IBD Society

2025 – Now Co-opted Council Member, Hong Kong Society of Gastroenterology

2024 – Now Governing Board Member, Asian Organization for Crohns and Colitis

### Main Scientific Publications

1. Zhang J\*, **Mak JWY**\*, Ng SC. Gut microbiome in IBD: past, present and the future. *Gut*. 2026 Jan 8;75(2):398 -410.
2. **Mak JWY**, Lo ATW, Ng SC. Early life factors, diet and microbiome, and risk of inflammatory bowel disease. *J Can Assoc Gastroenterol*. 2025 Feb 21;8(Suppl 2):S44-S50.
3. Solitano V, Bernstein CN, Dotan I, Dignass A, Domilici R, Dubinsky MC, Geary RB, Hart A, Kaplan GG, Ma C, Magro F, **Mak JWY**, Ng SC, Panaccione R, Raja S, Rubin DT, Siegel CA, Jairath V, Peyrin-Biroulet L, Danese S. Shaping the future inflammatory bowel disease: a global research agenda for better management and public health response. *Nat Rev Gastroenterol Hepatol*. 2025 Jun;22(6):438-452.

# AOCC 2026

## IMKASID 2026

JUNE 25 (Thu.) - 27 (Sat.), 2026 | COEX, SEOUL, KOREA



- 
4. **Mak, J. W. Y.**, Yuen, N. T. K., Yip, T. C. F., et al. No increased risk of flare in ulcerative colitis patients in corticosteroid remission after stopping 5-aminosalicylic acid: A territory-wide population-based study. *J Gastroenterol Hepatol.* 2022 Jul;37(7):1284-1289.
  5. **Mak, J.W.Y.**, F.K.L. Chan, and S.C. Ng, Probiotics and COVID-19: one size does not fit all. *Lancet Gastroenterol Hepa* 2020.
  6. Banerjee R, Pal P, **Mak JWY**, Ng SC. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. *Lancet Gastroenterol Hepatol.* 2020;5(12):1076-88.
  7. Ng SC, **Mak JWY**, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource -li settings in Asia. *Lancet Gastroenterol Hepatol.* 2020;5(12):1089-100.
-